The Study of CM326 in Moderate-to-severe Atopic Dermatitis
NCT ID: NCT05671432
Last Updated: 2023-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
240 participants
INTERVENTIONAL
2022-12-27
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
NCT05186922
The Study of CM326 in Adult Subjects With Atopic Dermatitis
NCT05671445
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
NCT05265923
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
NCT06277765
Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT05715320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A: CM326, subcutaneous (SC)
CM326
CM326 injection
Group B
Group A: CM326, subcutaneous (SC)
CM326
CM326 injection
Group C
Group C: placebo, subcutaneous (SC)
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CM326
CM326 injection
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years and ≤ 75 years, male or female.
* Have the ability to understand the nature of the study and voluntarily sign the informed consent.
* Be able to communicate well with investigators and follow up protocol requirements.
Exclusion Criteria
* Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.
* Major surgery is planned during the study period.
* Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keymed Biosciences Co.Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianzhong Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CM326-101102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.